1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10118
    Filibuvir
    Inhibitor ≥99.0%
    Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation.
    Filibuvir
  • HY-124648
    SMN-C2
    98.85%
    SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research.
    SMN-C2
  • HY-101813
    Laflunimus
    Inhibitor 99.70%
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
    Laflunimus
  • HY-W013068
    DMT-dT Phosphoramidite
    98.83%
    DMT-dT Phosphoramidite is typically used in the synthesis of DNA.
    DMT-dT Phosphoramidite
  • HY-156580
    WRN inhibitor 4
    Inhibitor 99.40%
    WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer.
    WRN inhibitor 4
  • HY-106014
    Tezacitabine
    Inhibitor 99.97%
    Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue. Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair. Tezacitabine effectively induces cells apoptotic. Tezacitabine has the potential for leukemias and solid tumors (carcinomas) treatment.
    Tezacitabine
  • HY-W017068
    dUTP trisodium
    99.74%
    dUTP trisodium is used for PCR.
    dUTP trisodium
  • HY-145724
    Drisapersen
    Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
    Drisapersen
  • HY-W016041
    2-Amino-2'-deoxyadenosine
    99.62%
    2-Amino-2'-deoxyadenosine is a deoxyribonucleoside used for the oligonucleotide synthesis.
    2-Amino-2'-deoxyadenosine
  • HY-145973A
    3'OMe-m7GpppAmpG (ammonium) solution (100mM)
    Modulator ≥99.0%
    3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization.
    3'OMe-m7GpppAmpG (ammonium) solution (100mM)
  • HY-W009538
    5'-Deoxy-5-fluorocytidine
    99.91%
    5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer.
    5'-Deoxy-5-fluorocytidine
  • HY-135218A
    AV-153 free base
    Activator 99.65%
    AV-153 free base, a 1,4-dihydropyridine (1,4-DHP) derivative, is an antimutagenic. AV-153 free base intercalates to DNA in a single strand break and reduces DNA damage, stimulates DNA repair in human cells in vitro. AV-153 free base interacts with thymine and cytosine and has an influence on poly(ADP)ribosylation. AV-153 free base has anti-cancer activity.
    AV-153 free base
  • HY-156581
    WRN inhibitor 5
    Inhibitor 98.12%
    WRN inhibitor 5, a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR).
    WRN inhibitor 5
  • HY-136499
    DI-82
    Inhibitor ≥98.0%
    DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC50app of 27.8 nM and Kiapp of 9.2 nM. DI-82 has antitumor activity.
    DI-82
  • HY-135282
    DHODH-IN-1
    Inhibitor 98.65%
    DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway.
    DHODH-IN-1
  • HY-N0007A
    Bisdemethoxycucurmin
    Inhibitor 98.96%
    Bisdemethoxycucurmin (Curcumin III) is a curcuminoid compound and an inhibitor of P-glycoprotein and ferroptosis. Bisdemethoxycucurmin exhibits multiple activities such as anti-oxidation, anti-inflammation and anti-tumor. Bisdemethoxycucurmin can be used for the research of tumors and inflammatory diseases.
    Bisdemethoxycucurmin
  • HY-N2384A
    Febrifugine dihydrochloride
    Inhibitor 99.95%
    Febrifugine dihydrochloride is a quinazolinone alkaloid that inhibits P. falciparum and has antimalarial activity. Febrifugine dihydrochloride inhibits bladder cancer by inhibiting DNA synthesis, inducing apoptosis, and reducing steroids.
    Febrifugine dihydrochloride
  • HY-158715
    3'-ONH2-dTTP (sodium) solution (100mM)
    99.00%
    3'-ONH2-dTTP sodium solution (100mM) is a labeled modified deoxyoligonucleotide (dNTP) that can release pyrophosphate to produce fluorescence and has special applications in gene synthesis and sequencing.
    3'-ONH2-dTTP (sodium) solution (100mM)
  • HY-W013053
    Dibenz[a,h]anthracene
    Inducer ≥98.0%
    Dibenz[a,h]anthracene (DBA) is a polycyclic aromatic hydrocarbon (PAH) of considerable tumorigenicity. Dibenz[a,h]anthracene results in DNA adduct formation leading to the activation of a DNA damage response. Dibenz[a,h]anthracene induces cell cycle arrest and apoptosis via both Tp53-dependent and Tp53-independent mechanisms.
    Dibenz[a,h]anthracene
  • HY-16662
    Oncrasin-1
    Inhibitor 98.16%
    Oncrasin-1 is an RNA polymerase inhibitor. Oncrasin-1 suppresses the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells. Oncrasin-1 effectively kills various human lung cancer cells with K-Ras mutations. Oncrasin-1 leads to coaggregation of PKCι and splicing factors into megaspliceosomes. Oncrasin-1 induces malfunction in the RNA processing machinery. Oncrasin-1 is an anti-cancer agent and can therefore be studied in research for lung cancer.
    Oncrasin-1
Cat. No. Product Name / Synonyms Application Reactivity